Severe adverse effects · people with metastatic CRC
Chemotherapy + bevacizumab showed no clear difference in severe adverse effects compared with chemotherapy (low certainty).
1 finding from 1 review
Severe adverse effects · people with metastatic CRC
Chemotherapy probably leads to higher severe adverse effects compared with best supportive care (moderate certainty).
1 finding from 1 review
Severe adverse effects · people with metastatic CRC
FOLFOX + targeted therapy leads to higher severe adverse effects compared with FOLFOX (high certainty).
1 finding from 1 review
Adverse effects: acute severe visual acuity decrease · people with neovascular age‐related macular degeneration
Photodynamic therapy with verteporfin showed no clear difference in adverse effects: acute severe visual acuity decrease compared with photodynamic therapy with 5% dextrose (moderate certainty).
1 finding from 1 review
Severe adverse effects · people with metastatic CRC
FOLFIRI + targeted therapy probably leads to higher severe adverse effects compared with FOLFIRI (moderate certainty).
1 finding from 1 review
Severe adverse effects · people with metastatic CRC
Modern chemotherapy regimens probably leads to higher severe adverse effects compared with 5‐flourouracil (moderate certainty).
1 finding from 1 review
Severe adverse effects · people with metastatic CRC
Irinotecan + targeted therapy leads to higher severe adverse effects compared with irinotecan (high certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ stoma formation (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ stoma… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ bowel resection (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ bowel… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ postoperative G3+ events (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ postoperative… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Investigator‐assessed severe adverse effects Blistering or scarring · Mild, moderate and severe acne vulgaris
1 finding from 1 review
Severe adverse effects · people with metastatic CRC
Irinotecan‐based regimens showed no clear difference in severe adverse effects compared with irinotecan (moderate certainty).
1 finding from 1 review
Severe adverse effects · people with metastatic CRC
Irinotecan + oxaliplatin probably leads to higher severe adverse effects compared with irinotecan (moderate certainty).
1 finding from 1 review
Intervention not reported
Severe adverse effects (G3/4) outcomes · Women with newly diagnosed epithelial ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found